Siegfried Holding AG

LSE:0QQO Stock Report

Market Cap: CHF 4.2b

Siegfried Holding Valuation

Is 0QQO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0QQO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0QQO (CHF974) is trading above our estimate of fair value (CHF463.91)

Significantly Below Fair Value: 0QQO is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0QQO?

Key metric: As 0QQO is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0QQO. This is calculated by dividing 0QQO's market cap by their current earnings.
What is 0QQO's PE Ratio?
PE Ratio32.4x
EarningsCHF 128.86m
Market CapCHF 4.18b

Price to Earnings Ratio vs Peers

How does 0QQO's PE Ratio compare to its peers?

The above table shows the PE ratio for 0QQO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.8x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
7.7x-29.6%UK£133.7m
HIK Hikma Pharmaceuticals
18.9x12.2%UK£4.3b
GNS Genus
126.1x31.5%UK£995.9m
0QQO Siegfried Holding
32.4x13.7%CHF 4.2b

Price-To-Earnings vs Peers: 0QQO is good value based on its Price-To-Earnings Ratio (32.4x) compared to the peer average (50.9x).

Price to Earnings Ratio vs Industry

How does 0QQO's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0QQO 32.4xIndustry Avg. 37.6xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0QQO is good value based on its Price-To-Earnings Ratio (32.4x) compared to the European Life Sciences industry average (38.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0QQO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0QQO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio32.4x
Fair PE Ratio24.3x

Price-To-Earnings vs Fair Ratio: 0QQO is expensive based on its Price-To-Earnings Ratio (32.4x) compared to the estimated Fair Price-To-Earnings Ratio (24.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0QQO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 974.00
CHF 1,187.67
+21.9%
11.6%CHF 1,500.00CHF 990.00n/a12
Dec ’25CHF 1,104.00
CHF 1,187.67
+7.6%
11.6%CHF 1,500.00CHF 990.00n/a12
Nov ’25CHF 1,150.00
CHF 1,187.67
+3.3%
11.6%CHF 1,500.00CHF 990.00n/a12
Oct ’25CHF 1,136.00
CHF 1,162.75
+2.4%
11.8%CHF 1,500.00CHF 990.00n/a12
Sep ’25CHF 1,118.10
CHF 1,075.15
-3.8%
7.8%CHF 1,188.00CHF 900.00n/a13
Aug ’25CHF 1,024.00
CHF 1,041.00
+1.7%
8.9%CHF 1,188.00CHF 880.00n/a12
Jul ’25CHF 944.00
CHF 1,015.90
+7.6%
7.4%CHF 1,125.00CHF 880.00n/a10
Jun ’25CHF 899.00
CHF 1,015.90
+13.0%
7.4%CHF 1,125.00CHF 880.00n/a10
May ’25CHF 882.00
CHF 1,015.90
+15.2%
7.4%CHF 1,125.00CHF 880.00n/a10
Apr ’25CHF 919.72
CHF 1,005.36
+9.3%
7.8%CHF 1,125.00CHF 880.00n/a11
Mar ’25CHF 905.00
CHF 964.55
+6.6%
7.2%CHF 1,050.00CHF 820.00n/a11
Feb ’25CHF 846.08
CHF 911.60
+7.7%
8.4%CHF 1,000.00CHF 800.00n/a10
Jan ’25CHF 860.66
CHF 891.22
+3.6%
7.5%CHF 990.00CHF 800.00n/a9
Dec ’24CHF 782.50
CHF 881.88
+12.7%
7.4%CHF 990.00CHF 800.00CHF 1,104.008
Nov ’24CHF 713.32
CHF 881.88
+23.6%
7.4%CHF 990.00CHF 800.00CHF 1,150.008
Oct ’24CHF 784.56
CHF 871.88
+11.1%
7.8%CHF 990.00CHF 800.00CHF 1,136.008
Sep ’24CHF 788.58
CHF 860.56
+9.1%
11.8%CHF 990.00CHF 640.00CHF 1,118.109
Aug ’24CHF 769.42
CHF 817.50
+6.2%
11.9%CHF 945.00CHF 640.00CHF 1,024.008
Jul ’24CHF 739.07
CHF 813.13
+10.0%
12.0%CHF 945.00CHF 640.00CHF 944.008
Jun ’24CHF 734.09
CHF 815.00
+11.0%
12.7%CHF 945.00CHF 640.00CHF 899.007
May ’24CHF 685.25
CHF 805.00
+17.5%
12.2%CHF 945.00CHF 640.00CHF 882.007
Apr ’24CHF 669.07
CHF 819.29
+22.5%
13.0%CHF 945.00CHF 640.00CHF 919.727
Mar ’24CHF 670.93
CHF 838.88
+25.0%
13.4%CHF 971.00CHF 640.00CHF 905.008
Feb ’24CHF 675.86
CHF 869.50
+28.7%
9.3%CHF 971.00CHF 700.00CHF 846.088
Jan ’24CHF 612.50
CHF 869.50
+42.0%
9.3%CHF 971.00CHF 700.00CHF 860.668
Dec ’23CHF 646.86
CHF 869.50
+34.4%
9.3%CHF 971.00CHF 700.00CHF 782.508

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 12:13
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Siegfried Holding AG is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Lopez PinedaBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Leonildo DelgadoBaader Helvea Equity Research